title: Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia.
abstract: The aim of the present study was to evaluate the factors that modulate the protective action of statins on cardiorenal function, regardless of the lipid-lowering effect. To treat abnormal serum lipid profiles, low-dose pitavastatin (1.0 mg/day) was administered to 65 hyperlipidemic patients. The exclusion criteria included left ventricular ejection fraction <40% and apparent renal disease. Age- and gender-matched patients with hyperlipidemia (n = 40) served as the controls. After 12 to 16 weeks of pitavastatin treatment, pitavastatin had decreased low-density lipoprotein cholesterol (from 143.5 ± 31.4 to 98.2 ± 19.4 mg/dl, p <0.01), triglycerides (from 157.7 ± 57.2 to 140.5 ± 60.7 mg/dl, p <0.01), E/e' (from 10.8 ± 6.2 to 9.0 ± 4.5, p <0.05), a parameter of left ventricular diastolic function, and albuminuria (from 47.6 ± 55.9 to 28.5 ± 40.0 mg/g creatinine, p <0.01). Furthermore, pitavastatin decreased serum transforming growth factor-β1 (from 709 ± 242 to 550 ± 299 pg/ml, p <0.01), urinary 8-hydroxy-2'-deoxyguanosine (from 6.6 ± 4.1 to 5.0 ± 3.1 μg/g creatinine, p <0.01), an oxidative stress marker, and increased urinary nitrate and nitrite (from 22.5 ± 14.6 to 29.4 ± 27.6 nmol/g creatinine, p <0.05). No such changes were observed in the controls. Multiple regression analysis in the pitavastatin group revealed the effect of pitavastatin on cardiorenal function was associated with suppression of oxidative stress, but not on low-density lipoprotein cholesterol reduction. In conclusion, pitavastatin decreases E/e' and albuminuria, which is associated with suppression of oxidative stress.
authors: Department of Cardiovascular Medicine, University of Tokushima Graduate School of Health Biosciences, Tokushima, Japan. syagi@clin.med.tokushima-u.ac.jp
authors: Shusuke
authors: S
authors: Yagi
authors: Masashi
authors: M
authors: Akaike
authors: Ken-Ichi
authors: K
authors: Aihara
authors: Takashi
authors: T
authors: Iwase
authors: Kazue
authors: K
authors: Ishikawa
authors: Sumiko
authors: S
authors: Yoshida
authors: Yuka
authors: Y
authors: Sumitomo-Ueda
authors: Kenya
authors: K
authors: Kusunose
authors: Toshiyuki
authors: T
authors: Niki
authors: Koji
authors: K
authors: Yamaguchi
authors: Kunihiko
authors: K
authors: Koshiba
authors: Yoshio
authors: Y
authors: Taketani
authors: Noriko
authors: N
authors: Tomita
authors: Hirotsugu
authors: H
authors: Yamada
authors: Takeshi
authors: T
authors: Soeki
authors: Tetsuzo
authors: T
authors: Wakatsuki
authors: Toshio
authors: T
authors: Matsumoto
authors: Masataka
authors: M
authors: Sata
mesh_terms: D000368:Aged; D000419:Albuminuria; D016022:Case-Control Studies; D008078:Cholesterol, LDL / Q000097:blood; D003971:Diastole / Q000187:drug effects*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; D014280:Triglycerides; C108475:pitavastatin